| pubmed-article:20405605 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20405605 | lifeskim:mentions | umls-concept:C0026769 | lld:lifeskim |
| pubmed-article:20405605 | lifeskim:mentions | umls-concept:C0034991 | lld:lifeskim |
| pubmed-article:20405605 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:20405605 | lifeskim:mentions | umls-concept:C0162791 | lld:lifeskim |
| pubmed-article:20405605 | lifeskim:mentions | umls-concept:C0348026 | lld:lifeskim |
| pubmed-article:20405605 | lifeskim:mentions | umls-concept:C1947933 | lld:lifeskim |
| pubmed-article:20405605 | lifeskim:mentions | umls-concept:C0521116 | lld:lifeskim |
| pubmed-article:20405605 | lifeskim:mentions | umls-concept:C1519814 | lld:lifeskim |
| pubmed-article:20405605 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:20405605 | pubmed:dateCreated | 2010-4-21 | lld:pubmed |
| pubmed-article:20405605 | pubmed:abstractText | Treatment is initiated when the McDonald criteria for relapsing-remitting multiple sclerosis (RRMS) are fulfilled. High-risk patients with clinically isolated syndrome are followed using magnetic resonance imaging for one year after the first imaging. Interferon-beta or glatiramer acetate are the first-line immunomodulating drugs (IMD) for RRMS. MxA protein is measured 12 and 24 months after initiation of Interferon-beta to evaluate possible development of neutralizing antibodies. If MxA protein may not be detected repeatedly interferon-beta treatment is discontinued. If the disease is active in spite of treatment with first-line IMD, natalizumab may be considered as a second-line therapy. IMD is stopped when the transition to secondary progressive phase has occurred (or upon transition to secondary progressive phase). | lld:pubmed |
| pubmed-article:20405605 | pubmed:language | fin | lld:pubmed |
| pubmed-article:20405605 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20405605 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20405605 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20405605 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20405605 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20405605 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20405605 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20405605 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20405605 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20405605 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20405605 | pubmed:issn | 0012-7183 | lld:pubmed |
| pubmed-article:20405605 | pubmed:author | pubmed-author:RuutiainenJuh... | lld:pubmed |
| pubmed-article:20405605 | pubmed:author | pubmed-author:FärkkiläMarku... | lld:pubmed |
| pubmed-article:20405605 | pubmed:author | pubmed-author:ElovaaraIrina... | lld:pubmed |
| pubmed-article:20405605 | pubmed:author | pubmed-author:AtulaSariS | lld:pubmed |
| pubmed-article:20405605 | pubmed:author | pubmed-author:ErälinnaJuha-... | lld:pubmed |
| pubmed-article:20405605 | pubmed:author | pubmed-author:PirttiläTuula... | lld:pubmed |
| pubmed-article:20405605 | pubmed:author | pubmed-author:Suomalaisen... | lld:pubmed |
| pubmed-article:20405605 | pubmed:author | pubmed-author:VarisTiinaT | lld:pubmed |
| pubmed-article:20405605 | pubmed:author | pubmed-author:RemesAnneA | lld:pubmed |
| pubmed-article:20405605 | pubmed:author | pubmed-author:Suomen... | lld:pubmed |
| pubmed-article:20405605 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:20405605 | pubmed:volume | 126 | lld:pubmed |
| pubmed-article:20405605 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20405605 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20405605 | pubmed:pagination | 199-200 | lld:pubmed |
| pubmed-article:20405605 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:20405605 | pubmed:meshHeading | pubmed-meshheading:20405605... | lld:pubmed |
| pubmed-article:20405605 | pubmed:meshHeading | pubmed-meshheading:20405605... | lld:pubmed |
| pubmed-article:20405605 | pubmed:meshHeading | pubmed-meshheading:20405605... | lld:pubmed |
| pubmed-article:20405605 | pubmed:meshHeading | pubmed-meshheading:20405605... | lld:pubmed |
| pubmed-article:20405605 | pubmed:meshHeading | pubmed-meshheading:20405605... | lld:pubmed |
| pubmed-article:20405605 | pubmed:meshHeading | pubmed-meshheading:20405605... | lld:pubmed |
| pubmed-article:20405605 | pubmed:meshHeading | pubmed-meshheading:20405605... | lld:pubmed |
| pubmed-article:20405605 | pubmed:meshHeading | pubmed-meshheading:20405605... | lld:pubmed |
| pubmed-article:20405605 | pubmed:meshHeading | pubmed-meshheading:20405605... | lld:pubmed |
| pubmed-article:20405605 | pubmed:meshHeading | pubmed-meshheading:20405605... | lld:pubmed |
| pubmed-article:20405605 | pubmed:meshHeading | pubmed-meshheading:20405605... | lld:pubmed |
| pubmed-article:20405605 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20405605 | pubmed:articleTitle | [Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis]. | lld:pubmed |
| pubmed-article:20405605 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20405605 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:20405605 | pubmed:publicationType | Practice Guideline | lld:pubmed |
